Investors Capital Advisory Services’s BioMarin Pharmaceuticals BMRN Stock Holding History

Investors Capital Advisory Services’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-1,500	Closed	-$205K	–	730
2015 Q2	$205K	Buy	+1,500	New	+$186K	0.04%	604

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Investors Capital Advisory Services's BMRN Position: Q3 2015 in Review

Investors Capital Advisory Services sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2015, closing a stake of 1,500 shares — an estimated $205K sold.

Investors Capital Advisory Services first reported a position in BMRN in Q2 2015 and held it in 1 quarter. The position peaked at $205K in Q2 2015. 394 funds tracked by Wall St. Rank hold BMRN as of Q3 2015.

Investors Capital Advisory Services reported no remaining BioMarin Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
Investors Capital Advisory Services sold 1,500 BioMarin Pharmaceuticals shares in Q3 2015, an estimated $205K.
Investors Capital Advisory Services first reported a position in BioMarin Pharmaceuticals in Q2 2015 and held it in 1 quarter.
Investors Capital Advisory Services's BioMarin Pharmaceuticals position peaked at $205K in Q2 2015.
394 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2015.

Based on Investors Capital Advisory Services's 13F filing for Q3 2015, filed 17 Nov 2015.